BACKGROUND: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV.
OBJECTIVE: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD).
METHOD: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data.
RESULTS: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups.
CONCLUSION: Patients with MDD can be safely and effectively treated with antiviral therapy.
Published In/Presented At
Hauser, P., Morasco, B. J., Linke, A., Bjornson, D., Ruimy, S., Matthews, A., … Loftis, J. M. (2009). Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics, 50(5), 500–505. https://doi.org/10.1176/appi.psy.50.5.500
Department of Psychiatry, Department of Psychiatry Faculty